Venture Life Regulatory News (VLG)

3 June 2020

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

AGM Statement

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, will hold its Annual General meeting ("AGM") this morning as a closed meeting. At the meeting, the Group's CEO, Jerry Randall, will make the following statement:

"Firstly, on behalf of the Board, I must pay tribute to all our incredible employees during the unprecedented challenges that have arisen as a result of COVID-19. Our manufacturing facility in northern Italy has worked tirelessly to maintain our business, our production and supply our customers with minimum disruption. Our commercial team has demonstrated great agility and a strong entrepreneurial spirit, in quickly responding to market demand for sanitising gel, and securing new partnership agreements within a matter of weeks.

As outlined on 27th April 2020, we announced the signing of an exclusive €168 million agreement with our existing Chinese partner for a number of the Group's products, including Dentyl, with orders in excess of €7 million for delivery in 2020.

With a robust long-term order book, a strong balance sheet and new commercial opportunities, we look forward to updating the market on our progress as the year progresses.

The Board would like to thank shareholders for their co-operation and understanding during these challenging and extraordinary times."

Venture Life's AGM is being held at 10.30 a.m. this morning as a closed meeting in light of the public health concerns surrounding the COVID-19 pandemic.

For further information, please contact:

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.